
CLAIMS

1. A medicament for the treatment or prevention of a cell proliferative disorder, the medicament comprising as an active ingredient a compound represented by formula (I):



(I)

or a pharmaceutically acceptable salt thereof, wherein the medicament is used in such a manner that:

(a) said compound or salt is administered twice weekly for 3 weeks,

(b) administration of said compound or salt is paused for the following 1 week, and

(c) steps (a) and (b) are subsequently repeated at least once.

2. The medicament according to claim 1, comprising a potassium salt of a compound represented by formula (I) as an active ingredient.

3. The medicament according to claim 1 or 2, wherein the cell proliferative disorder is cancer.

4. The medicament according to any one of claims 1 to 3, wherein the cell proliferative disorder is a KRAS mutant cancer.

5. The medicament according to any one of claims 1 to 4, wherein the cell proliferative disorder is a solid cancer.

6. The medicament according to any one of claims 1 to 5, wherein the dose per administration in step (a) is 3.2 mg.

7. The medicament according to claim 6, wherein the medicament is used in such a manner that prior to step (a):

(1) said compound or salt is administered twice weekly at a dose of 3.2 mg per administration; or

(2)

(2a) said compound or salt is administered twice weekly for 3 weeks at a dose of 4 mg per administration,

(2b) administration of said compound or salt is paused for the following 1 week, and

(2c) steps (2a) and (2b) are subsequently repeated at least once.

8. The medicament according to claim 7, wherein the medicament is used in such a manner that prior to step (1) or (2), said compound or salt is administered twice weekly at a dose of 4 mg per administration.

9. The medicament according to any one of claims 1 to 5:

wherein the medicament is used in such a manner that:

(A) first, said compound or salt is administered twice weekly at a dose of 4 mg per administration,

(B1) next, said compound or salt is administered twice weekly at

a dose of 3.2 mg per administration,

(C) after which:

(Ca) said compound or salt is administered twice weekly for 3 weeks at a dose of 3.2 mg per administration,

(Cb) administration of said compound or salt is paused for the following 1 week, and

(Cc) steps (Ca) and (Cb) are subsequently repeated at least once; or

wherein the medicament is used in such a manner that:

(A) first, said compound or salt is administered twice weekly at a dose of 4 mg per administration,

(B2) following which:

(B2a) said compound or salt is administered twice weekly for 3 weeks at a dose of 4 mg per administration,

(B2b) administration of said compound or salt is paused for the following 1 week, and

(B2c) steps (B2a) and (B2b) are subsequently repeated at least once; or

wherein the medicament is used in such a manner that:

(A) first, said compound or salt is administered twice weekly at a dose of 4 mg per administration,

(B2) following which:

(B2a) said compound or salt is administered twice weekly for 3 weeks at a dose of 4 mg per administration,

(B2b) administration of said compound or salt is paused for the following 1 week, and

(B2c) steps (B2a) and (B2b) are subsequently repeated at least once,

(C) after which:

(Ca) said compound or salt is administered twice weekly for 3 weeks at a dose of 3.2 mg per administration,

(Cb) administration of said compound or salt is paused for the following 1 week, and

(Cc) steps (Ca) and (Cb) are subsequently repeated at least once.

10. The medicament according to any one of claims 1 to 4, wherein the cell proliferative disorder is multiple myeloma.

11. The medicament according to claim 10, wherein the dose per administration in step (a) is 4 mg.


12. The medicament according to claim 10 or 11, wherein the cell proliferative disorder is an NRAS mutant cancer.

13. The medicament according to any one of claims 10 to 12, wherein the medicament is used in combination with dexamethasone, and wherein the medicament is used in such a manner that said compound or salt is administered before, simultaneously with or after administration of dexamethasone.

14. The medicament according to claim 13, wherein dexamethasone is administered once weekly at a dose of 20 mg per administration.

15. The medicament according to any one of claims 1 to 14, wherein the administration of said compound or salt is oral administration.

16. A medicament for the treatment or prevention of a cell proliferative disorder, the medicament comprising a compound represented by formula (I):



(I)

or a pharmaceutically acceptable salt thereof as an active ingredient, wherein the medicament is packaged together with:

(i) a container for housing said medicament, and

(ii) an instruction for using said medicament in such a manner that:

(a) said compound or salt is administered twice weekly for 3 weeks,

(b) administration of said compound or salt is paused for the following 1 week, and

(c) steps (a) and (b) are subsequently repeated at least once.

17. The medicament according to claim 16, wherein the medicament is a medicament according to any one of claims 1 to 15, and wherein the instruction is an instruction for using said medicament in such a manner

that said compound or salt is administered according to the prescribed dosing regimen corresponding to the medicament used.